| . | All patients (n = 162) . | WACA group (n = 81) . | Ostial group (N = 81) . | P-value . |
|---|---|---|---|---|
| Male gender, n (%) | 103 (64) | 52 (64) | 51 (63) | 0.87 |
| Age, years (mean ± SD) | 58 ± 10 | 58 ± 8 | 57 ± 12 | 0.71 |
| BMI, kg/m2 (mean ± SD) | 26.8 ± 4.1 | 27.0 ± 4.4 | 26.5 ± 4.0 | 0.23 |
| Hypertension, n (%) | 86 (53) | 39 (48) | 47 (58) | 0.21 |
| Diabetes mellitus, n (%) | 22 (14) | 11 (14) | 11 (14) | 0.18 |
| Stroke history, n (%) | 8 (5) | 5 (6) | 3 (4) | 0.48 |
| Congestive heart failure, n (%) | 9 (6) | 4 (5) | 5 (6) | 0.72 |
| Sleep apnoea, n (%) | 7 (4) | 2 (3) | 5 (6) | 0.16 |
| Thyroid disease, n (%) | 21 (13) | 7 (9) | 14 (18) | 0.11 |
| Clearance of creatinine (mL/min), mean ± SD | 90 ± 25 | 87 ± 15 | 93 ± 32 | 0.22 |
| CHA2DS2-VASc score (median, Q1–Q3) | 1 (1–2) | 2 (1–2) | 1 (1–2) | 0.12 |
| First AF episode to PVI, months (median, Q1–Q3)) | 40(24–80) | 48 (25–92) | 38(22–73) | 0.21 |
| Previous electric cardioversion, n (%) | 49 (32) | 21 (27) | 28 (37) | 0.17 |
| LVEF, % (mean ± SD) | 60 ± 6 | 60 ± 7 | 61 ± 5 | 0.50 |
| LA diameter (mm), (mean ± SD) | 40 ± 6 | 40 ± 5 | 40 ± 6 | 0.64 |
| . | All patients (n = 162) . | WACA group (n = 81) . | Ostial group (N = 81) . | P-value . |
|---|---|---|---|---|
| Male gender, n (%) | 103 (64) | 52 (64) | 51 (63) | 0.87 |
| Age, years (mean ± SD) | 58 ± 10 | 58 ± 8 | 57 ± 12 | 0.71 |
| BMI, kg/m2 (mean ± SD) | 26.8 ± 4.1 | 27.0 ± 4.4 | 26.5 ± 4.0 | 0.23 |
| Hypertension, n (%) | 86 (53) | 39 (48) | 47 (58) | 0.21 |
| Diabetes mellitus, n (%) | 22 (14) | 11 (14) | 11 (14) | 0.18 |
| Stroke history, n (%) | 8 (5) | 5 (6) | 3 (4) | 0.48 |
| Congestive heart failure, n (%) | 9 (6) | 4 (5) | 5 (6) | 0.72 |
| Sleep apnoea, n (%) | 7 (4) | 2 (3) | 5 (6) | 0.16 |
| Thyroid disease, n (%) | 21 (13) | 7 (9) | 14 (18) | 0.11 |
| Clearance of creatinine (mL/min), mean ± SD | 90 ± 25 | 87 ± 15 | 93 ± 32 | 0.22 |
| CHA2DS2-VASc score (median, Q1–Q3) | 1 (1–2) | 2 (1–2) | 1 (1–2) | 0.12 |
| First AF episode to PVI, months (median, Q1–Q3)) | 40(24–80) | 48 (25–92) | 38(22–73) | 0.21 |
| Previous electric cardioversion, n (%) | 49 (32) | 21 (27) | 28 (37) | 0.17 |
| LVEF, % (mean ± SD) | 60 ± 6 | 60 ± 7 | 61 ± 5 | 0.50 |
| LA diameter (mm), (mean ± SD) | 40 ± 6 | 40 ± 5 | 40 ± 6 | 0.64 |
AF, atrial fibrillation; BMI, body mass index; LA, left atrium; LVEF, left ventricle ejection fraction; PVI, pulmonary vein isolation; SD, standard deviation; WACA, wide-area circumferential ablation.
| . | All patients (n = 162) . | WACA group (n = 81) . | Ostial group (N = 81) . | P-value . |
|---|---|---|---|---|
| Male gender, n (%) | 103 (64) | 52 (64) | 51 (63) | 0.87 |
| Age, years (mean ± SD) | 58 ± 10 | 58 ± 8 | 57 ± 12 | 0.71 |
| BMI, kg/m2 (mean ± SD) | 26.8 ± 4.1 | 27.0 ± 4.4 | 26.5 ± 4.0 | 0.23 |
| Hypertension, n (%) | 86 (53) | 39 (48) | 47 (58) | 0.21 |
| Diabetes mellitus, n (%) | 22 (14) | 11 (14) | 11 (14) | 0.18 |
| Stroke history, n (%) | 8 (5) | 5 (6) | 3 (4) | 0.48 |
| Congestive heart failure, n (%) | 9 (6) | 4 (5) | 5 (6) | 0.72 |
| Sleep apnoea, n (%) | 7 (4) | 2 (3) | 5 (6) | 0.16 |
| Thyroid disease, n (%) | 21 (13) | 7 (9) | 14 (18) | 0.11 |
| Clearance of creatinine (mL/min), mean ± SD | 90 ± 25 | 87 ± 15 | 93 ± 32 | 0.22 |
| CHA2DS2-VASc score (median, Q1–Q3) | 1 (1–2) | 2 (1–2) | 1 (1–2) | 0.12 |
| First AF episode to PVI, months (median, Q1–Q3)) | 40(24–80) | 48 (25–92) | 38(22–73) | 0.21 |
| Previous electric cardioversion, n (%) | 49 (32) | 21 (27) | 28 (37) | 0.17 |
| LVEF, % (mean ± SD) | 60 ± 6 | 60 ± 7 | 61 ± 5 | 0.50 |
| LA diameter (mm), (mean ± SD) | 40 ± 6 | 40 ± 5 | 40 ± 6 | 0.64 |
| . | All patients (n = 162) . | WACA group (n = 81) . | Ostial group (N = 81) . | P-value . |
|---|---|---|---|---|
| Male gender, n (%) | 103 (64) | 52 (64) | 51 (63) | 0.87 |
| Age, years (mean ± SD) | 58 ± 10 | 58 ± 8 | 57 ± 12 | 0.71 |
| BMI, kg/m2 (mean ± SD) | 26.8 ± 4.1 | 27.0 ± 4.4 | 26.5 ± 4.0 | 0.23 |
| Hypertension, n (%) | 86 (53) | 39 (48) | 47 (58) | 0.21 |
| Diabetes mellitus, n (%) | 22 (14) | 11 (14) | 11 (14) | 0.18 |
| Stroke history, n (%) | 8 (5) | 5 (6) | 3 (4) | 0.48 |
| Congestive heart failure, n (%) | 9 (6) | 4 (5) | 5 (6) | 0.72 |
| Sleep apnoea, n (%) | 7 (4) | 2 (3) | 5 (6) | 0.16 |
| Thyroid disease, n (%) | 21 (13) | 7 (9) | 14 (18) | 0.11 |
| Clearance of creatinine (mL/min), mean ± SD | 90 ± 25 | 87 ± 15 | 93 ± 32 | 0.22 |
| CHA2DS2-VASc score (median, Q1–Q3) | 1 (1–2) | 2 (1–2) | 1 (1–2) | 0.12 |
| First AF episode to PVI, months (median, Q1–Q3)) | 40(24–80) | 48 (25–92) | 38(22–73) | 0.21 |
| Previous electric cardioversion, n (%) | 49 (32) | 21 (27) | 28 (37) | 0.17 |
| LVEF, % (mean ± SD) | 60 ± 6 | 60 ± 7 | 61 ± 5 | 0.50 |
| LA diameter (mm), (mean ± SD) | 40 ± 6 | 40 ± 5 | 40 ± 6 | 0.64 |
AF, atrial fibrillation; BMI, body mass index; LA, left atrium; LVEF, left ventricle ejection fraction; PVI, pulmonary vein isolation; SD, standard deviation; WACA, wide-area circumferential ablation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
